Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nevro reports strong Q4 earnings, eyes market growth opportunities

Nevro's Q4 2022 performance reflects revenue growth, strong trial rates, and market share gains, with expectations for continued growth.
Challenges include pandemic impact, pricing pressure, and questions on clinical benefits quantification and CEO search progress.
Opportunities lie in market share gains, differentiation through HFX iQ System, and engagement with payers for PDN and NSRBP.
Overall, Nevro anticipates gradual growth throughout 2023, with minimal impact expected from new competitors like Medtronic and Abbott.

Nevro surpasses Q1 expectations, poised for sustained growth ahead

Nevro's Q1 performance exceeded expectations, showcasing strong growth and positive market reception. With a focus on disruptive technologies, new product launches, and market expansion, the company is well-positioned for continued success amidst optimistic market dynamics.

Nevro reports solid Q2 results, focuses on market growth strategies

Nevro's Q2 2023 performance showed revenue growth and focus on market penetration, with challenges in sales force turnover and competition.
Strengths lie in expanded PDN coverage, clinical data emphasis, and reimbursement wins, while opportunities include market growth and enhanced sales productivity.
Addressing challenges through realignment efforts and compensation plans, Nevro aims to leverage market opportunities and drive profitability in the coming months.
Guidance considers turnover impact, territory rebuilding, and sustained business through therapy consultants, positioning Nevro for future growth and success.

Nevro excels in Q3 earnings, eyes growth through innovative therapies

Nevro's Q3 performance reflects strong revenue growth and success in the PDN market, driven by innovative SCS therapy solutions.
The company's strategic focus on commercial execution, market penetration, and operational efficiencies positions them for future success.
Challenges include increasing market penetration, balancing margin expansion with operational efficiency, and careful consideration of acquisitions.
Opportunities lie in leveraging low market penetration, enhancing customer engagement, and collaborating with key experts for continued growth.

Nevro reports solid Q4 revenue growth, eyes market expansion

Nevro's Q4 2023 performance reflects revenue growth driven by PDN sales, with positive EBITDA and strategic acquisitions enhancing market positioning.
While challenges in operational profitability persist, Nevro's focus on market penetration, physician engagement, and salesforce effectiveness present growth opportunities.
Analyst inquiries into market dynamics, competition, and product differentiation underscore the need for Nevro to navigate operational challenges and capitalize on growth prospects.

Nevro surpasses Q1 expectations, eyes market expansion and margin growth

Nevro's Q1 2024 performance exceeded guidance, driven by HFX iQ and increased replacement device candidates, with restructuring efforts to generate savings in 2024.
Strengths include FDA clearance for Nevro1 in SI joint fusion, Android compatibility for HFX iQ, and focus on expanding market penetration.
Challenges include U.S. trials decline, COGS pressure anticipated, and ensuring sales reps are up to speed, while opportunities lie in expanding margins and market penetration.
Overall, Nevro's strategic focus on SI joint fusion products and margin expansion positions them for growth in 2025 and beyond.

Nevro faces revenue decline but pursues strategic growth initiatives

Nevro's Q2 performance reflects revenue challenges but maintains a positive adjusted EBITDA amidst market pressures.
The company's strategic focus on diversification, commercial execution, and exploring strategic options highlights a proactive approach to driving growth.
With a strong cash position and ongoing efforts to navigate challenges and capitalize on opportunities, Nevro is poised for future success.

Nevro reports revenue decline in Q3 but advances AI therapy

Nevro faced revenue decline in Q3 2024 but maintained stability and improved cash position.
Strategic actions to enhance commercial execution and product innovation show promise for future growth.
Challenges in revenue and profitability persist, but opportunities in therapy expansion and market diversification exist.
Continued focus on cost management and strategic exploration to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Wall Street cheers after the company announced a surprise change in the corner office. Here's what investors need to know.

Here's Why Nevro Is Skyrocketing Today

Nevro's (NVRO) solid domestic and international performance aids Q4 results.

Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat

News for Nevro Stock (NVRO)